The vaccine can be very effective in preventing the serious occurrence of Cold-19, even against the delta type, an extensive study in France shows.
Research released on Monday – focusing on preventing severe goiter and death, not infection – looked at 22 million people over the age of 50 and found that 90 percent of those who received jabs would be hospitalized or die.
The results confirm the observations of the United States, the United Kingdom and Israel, but researchers say this is the largest study of its kind.
Looking at the data collected in December 2020, when France launched its Jab campaign, researchers compared the results of 11 million vaccinated people with 11 million non-vaccinated subjects.
They created pairs that matched the vaccinated person to the same area of the vaccinated person and of the same age and gender, and monitored them from the second jab of the vaccinated person until July 20.
14 days after the second dose, the risk of severe goiter from those vaccinated was reduced by 90 percent, according to a study by AB-Farey, a self-medication safety research team that will close with the French government.
Vaccination against the delta type is most effective, with 84 percent protection for those 75 years of age and older and 92 percent protection for 50-75 people.
However, that estimate is based on one-month data only, as this variation only dominated France in June.
“We need to continue the study, which includes the results of August and September,” Mahmoud Zurich, the epidemiologist and head of AB-Fora, told AFP.
This study includes the vaccine with Pfizer / Bioendech, Moderna and Astrogeneneka jabs, but not Johnson, which was later approved and used much less in France.
The results also show that severe Govt vaccine coverage did not decrease during the study – up to five months.
(This story was not edited by NDTV staff and was automatically created from Syndicate Feed.)